IDO1 and neoplasm: IDO inhibition and the PD-L1 blockade triggered the immune response, enhancing tumor infiltration by lymphocytes, including T cells and NK cells, and suppressing Tregs and the production of IFN-γ in CT26 colon cancer cells [174].